U.S., July 12 -- ClinicalTrials.gov registry received information related to the study (NCT07060417) titled 'Vascular Effects of SGLT2i in Non-diabetic CKD' on July 01.
Brief Summary: Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney disease (CKD) and heart failure and improves exercise tolerance regardless of the diabetes status. One of the important ways that empagliflozin improves health may be through its benefits on blood vessels. The effects of empagliflozin on blood vessels and physical function have not been examined in patients with chronic kidney disease, and it is less clear if empagliflozin may be beneficial in patients with...